Metraipolis › archive › dc_331a292828d9

Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based… — Europe PMC PMID:41283233

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41283233
DOI
10.3390/hematolrep17060057
License (as archived)
solo-consultazione
Archived
2026-11-08T23:30:05.125Z
SHA-256 of the archived text
1381f767aed5396f83754d01cc17f5d967a0b13eb74c5e05e7ba97af19987357
Stable URL of this page
https://metraipolis.com/documento/dc_331a292828d9

How to cite

Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based… — Europe PMC PMID:41283233 — Europe PMC (en), https://europepmc.org/article/MED/41283233 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_331a292828d9 (Metraipolis archive dc_331a292828d9, sha256 1381f767aed5396f83754d01cc17f5d967a0b13eb74c5e05e7ba97af19987357)
BibTeX
@misc{dc331a292828d9,
  title = {Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based… — Europe PMC PMID:41283233},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41283233},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_331a292828d9; sha256 1381f767aed5396f83754d01cc17f5d967a0b13eb74c5e05e7ba97af19987357},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41283233. Agents can read the archived copy with the MCP tool read_document.